Results 181 to 190 of about 1,868 (233)

Droxidopa in the Management of Hepatorenal Syndrome

Journal of Pharmacy Practice, 2022
Purpose Hepatorenal syndrome (HRS) is renal dysfunction associated with the hemodynamic consequences of advanced liver disease and cirrhosis. HRS is associated with a high mortality, and there remain high failure rates with first-line therapy aimed at improving perfusion. We report the use of droxidopa, an oral norepinephrine precursor, to aid in the
Andrea Bejjani, Youqi Zhang, Allison Behrens, Brian Murray, Neil Shah   +4 more
openaire   +3 more sources

Successful Treatment of Refractory Orthostatic Intolerance (OI) With Droxidopa

Clinical Pediatrics, 2022
Orthostatic intolerance (OI) is a disorder of the autonomic nervous system characterized by the provocation of symptoms with standing and the improvement in symptoms with recumbency.1 In adults, postural orthostatic tachycardia syndrome (POTS), a form of
Christina Kokorelis, Joann Bodurtha, Kelsey Guthrie, Peter C. Rowe   +3 more
openaire   +3 more sources

Method Development and Validation of Droxidopa by RP-UPLC

Research Journal of Pharmacy and Technology, 2021
A simple, rapid, accurate and economical method has been developed for the quantification of droxidopa by UPLC. The chromatographic system was equipped with Phenomenex column C18 (50mm x 3.0mm, 3µ) as stationary phase and UV detector at 235nm, in conjunction with a mobile phase of buffer: methanol (25:75 % v/v ratio) at a flow rate of 1.0mL/min ...
Bharani Pandilla, K. Chitra, C. N. Nalini, Ashok P   +3 more
exaly   +4 more sources

Droxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients.

Journal of Cardiothoracic and Vascular Anesthesia, 2023
OBJECTIVE To evaluate the effects of droxidopa or atomoxetine on intravenous (IV) vasoactive agent discontinuation in cardiothoracic intensive care unit (ICU) patients with hypotension refractory to midodrine. DESIGN Single-center, retrospective cohort
Julia Lessing, Shawn J. Kram, Jerrold H. Levy, L. Grecu, Jason N. Katz   +4 more
semanticscholar   +1 more source

Droxidopa

Reactions weekly
openaire   +2 more sources

Oral Vasoactive Medications: A Summary of Midodrine and Droxidopa as Applied to Orthostatic Dysfunction

Cardiology: Open Access, 2022
This is a summary of the uses and applications of two vasoactive drugs, Midodrine (ProAmatine) and Droxidopa (Northera), in the treatment of Orthostatic Dysfunction (OD) disorders, including Neurogenic Orthostatic Hypotension, Postural Orthostatic ...

semanticscholar   +1 more source

Droxidopa for neurogenic orthostatic hypotension [PDF]

Expert Opinion on Orphan Drugs, 2015
Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinson’s disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that ...
openaire   +1 more source

Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome

American Journal of Therapeutics, 2017
Background: Postural orthostatic tachycardia syndrome (POTS) is a constellation of signs and symptoms that occur when a patient is upright and relieved by recumbence. Currently, no drugs are labeled for the treatment for POTS.
Mohammed Ruzieh, Osama Dasa, Blair P Grubb   +2 more
exaly   +4 more sources

Droxidopa for orthostatic hypotension

Journal of Hypertension, 2016
The systematic review and meta-analysis aims to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension, following its recent approvals in the United States.MEDLINE, EMBASE, PubMed, Cochrane Controlled Trials Register, Web of Science, ProQuest, and the WHO Clinical Trials Registry were searched.
Julia L Newton, Maw Pin Tan, James Frith
exaly   +4 more sources

Pilot Study of Droxidopa With Carbidopa in Adults With ADHD

Journal of Attention Disorders, 2015
Objective: We conducted a two-period (open-label and double-blind) pilot investigation of droxidopa, with and without carbidopa, for ADHD. Method: Twenty adult ADHD patients received open-label droxidopa titrated from 200 to 600 mg 3 times per day (TID; Weeks 1-3), then open-label droxidopa plus carbidopa titrated from 25 or 50 mg TID (Weeks 4-6).
Stephen W. Gorny, Lenard A. Adler
openaire   +3 more sources